Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hospital price data updated

This article was originally published in The Gray Sheet

Executive Summary

CMS updates hospital-specific volume and payment data for 31 common inpatient procedures on its 1Web site June 21. Intended to increase transparency for consumers, data on the procedures was first posted last June (2"The Gray Sheet" June 5, 2006, In Brief). According to the update, in fiscal year 2006 the midrange of payments for implantable defibrillator implants with cardiac catheterization was $37,102-$48,790, and charges averaged $135,717. For major joint replacements, the payment range was $10,085-$12,257 with average charges of $38,447. CMS plans to update the data for common outpatient, ambulatory surgical center and physician services later this summer and fall...

You may also be interested in...



Hospital price data published

CMS posts payment information on its website for the 30 most common elective procedures and reasons for admissions, including implantation of defibrillators and hip and knee replacements. Posted June 1 to kick off the agency's transparency initiative, the data shows the service volumes and Medicare payment ranges for all hospitals by county to help consumers compare price and quality of care (1"The Gray Sheet" March 20, 2006, p. 13). The agency plans to add geographically based payment information for ambulatory surgery centers this summer, and outpatient and physician services in the fall...

Health And Wellness Trademark Review 1 December, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Ipsen CEO Outlines Strategy For Long-Term Success

While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel